Evidence map›Paper›PMID 37322994›Full record

ArticleAnnals of medicine2023

Costs of psychotropics for outpatients with bipolar disorder in Japan; the MUSUBI 2016 survey.

Naoto Adachi, Yukihisa Kubota, Eiichiro Goto, Koichiro Watanabe, Reiji Yoshimura, Takashi Tsuboi, Norio Yasui-Furukori, Masaki Kato, Seiji Hongo, Takaharu Azekawa and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Naoto AdachiAdachi Mental Clinic Sapporo, Kiyota Sapporo, Japan.ORCID 0000-0001-8376-4900
Yukihisa KubotaChuo-Koen Clinic, Fuji, Japan.
Eiichiro GotoShinwado Goto Clinic, Fukuoka, Japan.
Koichiro WatanabeDepartment of Neuropsychiatry, Kyorin University, School of Medicine, Mitaka, Japan.ORCID 0000-0002-0736-7070
Reiji YoshimuraDepartment of Psychiatry, University of Occupational and Environment Health, Kitakyushu, Japan.ORCID 0000-0002-7637-5576
Takashi TsuboiDepartment of Neuropsychiatry, Kyorin University, School of Medicine, Mitaka, Japan.ORCID 0000-0002-8253-8888
Norio Yasui-FurukoriDepartment of Psychiatry, Dokkyo Medical University, Mibu, Japan.ORCID 0000-0002-4414-3770
Masaki KatoDepartment of Neuropsychiatry, Kansai Medical University, Osaka, Japan.ORCID 0000-0001-6727-7272
Seiji HongoIchigaya Himorogi Clinic, Tokyo, Japan.
Takaharu AzekawaShioiri Mental Clinic, Yokosuka, Japan.
Eiichi KatsumotoKatsumoto Mental Clinic, Osaka, Japan.
Koji EdagawaEdagawa Clinic, Tokushima, Japan.
Atsuo NakagawaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0002-2294-2571
Toshiaki KikuchiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0003-1025-8796
Hitoshi UedaMorioka Kokoro-no Clinic, Morioka, Japan.
Kazuhira MikiMiki Mental Clinic, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the costs of bipolar disorder (BD) treatments are associated with local and universal factors, data from non-Western countries remain limited. The associations between clinical features and costs of outpatient pharmacotherapy have not been well characterize. To estimate the costs of outpatient BD treatments and their associations with clinical features in a Japanese population, we investigated with special reference to the costs of medicines constituted the bulk of the total healthcare expense and were steadily increasing.

methodsThe Multicenter Treatment Survey for Bipolar Disorder (MUSUBI) retrospectively evaluated 3130 patients with BD who visited 176 Japanese psychiatric outpatient clinics in 2016. Clinical features and drug prescriptions were recorded, and the total daily costs of psychotropic drug treatment were calculated. The annual medical costs related to outpatient BD treatments in Japan were estimated based on the corresponding demographics. The associations between daily medical costs and patients' clinical features were analyzed using multiple regression analysis.

resultsThe daily costs of psychotropic drugs ranged from zero to JPY3245 (mean, JPY349 equivalent to USD32.5) and were exponentially distributed. The annual costs for outpatients BD treatments were approximately 51.9 billion Japanese yens (519 million US dollars). Subsequent multiple regression analysis revealed that social adjustment, depressive symptoms, age, rapid cycling, psychotic symptoms, and comorbid mental disorders correlated strongly with the daily cost of psychotropic drugs.

conclusionThe estimated annual costs for outpatient BD treatment in Japan were equivalent to those in OECD countries (except for the US) and higher than those in some Asian countries. The cost of psychotropic treatments was associated with individual characteristics and psychopathological conditions.Key MessagesPsychotropic treatment for an outpatient with bipolar disorder has a daily cost approximately JPY350.The annual outpatient treatment cost for bipolar disorder in Japan was estimated to 51.9 billion Japanese yen in 2016.Individual characteristics and psychopathological conditions affected the cost of drug treatment.

Indexed as

Bipolar DisorderHumansJapanOutpatientsPsychotropic DrugsRetrospective StudiesPsychotropic DrugsBipolar disordermedicationoutpatient treatmentpsychopharmacology

Identifiers

PMID37322994
PMCPMC10281415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.